Proteolysis targeting chimera (PROTAC) is an emerging pharmacological modality with
innovated post‐translational protein degradation capabilities. However, off‐target induced …

Proteolysis-targeting chimera (PROTAC) technology represents a novel and promising
modality for targeted protein degradation with transformative implications for the clinical …

Proteolysis-targeting chimeras (PROTACs) have shown great therapeutic potential by
degrading various disease-causing proteins, particularly those related to tumors. Therefore …

Proteolysis targeting chimera (PROTAC) technology is a chemical protein knockdown
approach that degrades protein by hijacking the cellular ubiquitin-proteasome system to …

Abstract PROteolysis TArgeting Chimeras (PROTACs) has been exploited to degrade
putative protein targets. However, the antitumor performance of PROTACs is impaired by …

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for
targeted protein degradation. A bifunctional PROTAC molecule consists of a ligand (mostly …

Protein degradation mediated by the proteolysis-targeting chimera (PROTAC) has emerged
as an efficient strategy to accurately control intracellular protein levels. However, the …

Proteolysis-targeting chimera (PROTAC) is emerging as a new strategy to degrade target
proteins in a precise way by taking advantage of the cellular ubiquitin-proteasome system …

Abstract Proteolysis Targeting Chimeras (PROTACs) represent a promising therapeutic
modality to address undruggable and resistant issues in drug discovery. However, potential …

Proteolysis Targeting Chimeras (PROTACs), an emerging therapeutic entity designed to
degrade target proteins by hijacking the ubiquitin–proteasome system, have the potential to …